China’s Fosun Pharma to import 100 million BioNTech vaccine doses

Photo credit: Pixabay / CC0 Public Domain

A Chinese pharmaceutical company announced Wednesday that it had agreed to buy at least 100 million doses of the coronavirus vaccine from German company BioNTech, provided Beijing approves its use.

China quickly developed its own COVID-19 vaccine candidates and ramped up production facilities, but local firms have also partnered with overseas developers to supply the world’s most populous country.

Shanghai Fosun Pharmaceutical Group announced that its subsidiary has reached an agreement with the German company aimed at ensuring “adequate supplies” of vaccines in China. An initial payment of 125 million euros ($ 50 million) will be made by year-end for 50 million cans.

Fosun Pharma announced that it will pay the remaining 125 million euros after receiving approval to market the German vaccine in mainland China.

The agreement did not specify when the remaining 50 million cans would arrive.

Pfizer and BioNTech’s mRNA vaccine has already been approved for emergency use in countries such as the US, UK and Singapore.

The vaccine is based on cutting edge technology that uses synthetic versions of molecules called messenger RNA to hack into human cells and effectively convert them into vaccine factories.

Five vaccines are in the final stages of development in Beijing. At least a million people should receive a sting after the emergency vaccine candidates are approved.

China has reached agreements to ship millions of doses of Chinese-made vaccines to other countries after the outbreak was largely brought under control at home.

On Tuesday, health officials in a district in northern Heilongjiang Province where officials had battled a small number of cases said they would offer doses of COVID-19 vaccine to the public.

The shocks cost 420 yuan (US $ 64), but the statement didn’t make it clear which vaccine was being offered.

Three of China’s five vaccine products that are in the final stages of development use an inactivated form of the novel coronavirus to boost immunity.

Fosun Pharma is majority-owned by Fosun International, a Chinese conglomerate that owns France-based resort giant Club Med and travel company Thomas Cook.

Follow the latest news on the Coronavirus (COVID-19) outbreak

© 2020 AFP

Quote: China’s Fosun Pharma imports 100 million BioNTech vaccine doses (2020, December 16), accessed December 16, 2020 from

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.

Comments are closed.